Breast cancer: Bisphosphonate therapy for metastatic bone disease

被引:48
作者
Body, Jean-Jacques [1 ]
机构
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Internal Med, B-1000 Brussels, Belgium
关键词
D O I
10.1158/1078-0432.CCR-06-0840
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The indications of bisphosphonate therapy in breast cancer patients go from the correction of hypercalcemia to the prevention of cancer treatment-induced bone loss. Bisphosphonates are part of our therapeutic armamentarium against metastatic bone pain, and at least 50% of the patients benefit from a clinically relevant analgesic effect. Placebo-controlled trials with oral or i.v. bisphosphonates have shown that prolonged administration can reduce the frequency of skeletal-related events by 30% to 40%. The superiority of zoledronic acid compared with pamidronate has been shown by a multiple-event analysis in a large randomized trial. The short infusion time of zoledronic acid also constitutes a convenient therapy. Where available oral ibandronate offers an interesting alternative especially for patients receiving hormone therapy. There are some toxicity concerns with the prolonged use of bisphosphonates. The occasional renal toxicity of zoledronic acid has led to the recommendation to monitor renal function before each infusion and to adjust the dose according to creatine clearance. Osteonecrosis of the jaw could occur in up to 2.5% of breast cancer patients during long-term bisphosphonate therapy. It is often a significant complication that seems to be linked with the duration of therapy.
引用
收藏
页码:6258S / 6263S
页数:6
相关论文
共 40 条
  • [1] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [2] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Body, JJ
    Facon, T
    Coleman, RE
    Lipton, A
    Geurs, F
    Fan, M
    Holloway, D
    Peterson, MC
    Bekker, P
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1221 - 1228
  • [3] Body JJ, 2000, CANCER AND THE SKELETON, P231
  • [4] Current use of bisphosphonates in oncology
    Body, JJ
    Bartl, R
    Burckhardt, P
    Delmas, PD
    Diel, IJ
    Fleisch, H
    Kanis, JA
    Kyle, RA
    Mundy, GR
    Paterson, AHG
    Rubens, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3890 - 3899
  • [5] Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis
    Body, JJ
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 567 - 580
  • [6] Dosing regimens and main adverse events of bisphosphonates
    Body, JJ
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 49 - 53
  • [7] Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
    Body, JJ
    Diel, IJ
    Lichinitzer, M
    Lazarev, A
    Pecherstorfer, M
    Bell, R
    Tripathy, D
    Bergstronn, B
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (06) : 1133 - 1137
  • [8] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    Body, JJ
    Diel, IJ
    Lichinitser, MR
    Kreuser, ED
    Dornoff, W
    Gorbunova, VA
    Budde, M
    Bergström, B
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (09) : 1399 - 1405
  • [9] Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer
    Body, JJ
    Diel, IJ
    Bell, R
    Pecherstorfer, M
    Lichinitser, MR
    Lazarev, AF
    Tripathy, D
    Bergström, B
    [J]. PAIN, 2004, 111 (03) : 306 - 312
  • [10] BODY JJ, 2006, PRIMER METABOLIC BON, P383